What is a stock summary page? Click here for an overview.
Business Description
OmniAb Inc
NAICS : 541714
SIC : 2834
ISIN : US68218J1034
Description
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.57 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.46 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 3.15 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.2 | |||||
| 3-Year EBITDA Growth Rate | -46.5 | |||||
| 3-Year EPS without NRI Growth Rate | -37.2 | |||||
| 3-Year FCF Growth Rate | -68.4 | |||||
| 3-Year Book Growth Rate | 5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.99 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 27.49 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.11 | |||||
| 9-Day RSI | 17.16 | |||||
| 14-Day RSI | 22.06 | |||||
| 3-1 Month Momentum % | -4.76 | |||||
| 6-1 Month Momentum % | -13.27 | |||||
| 12-1 Month Momentum % | -35.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.52 | |||||
| Quick Ratio | 4.52 | |||||
| Cash Ratio | 3.94 | |||||
| Days Sales Outstanding | 65.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -3.68 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -282.3 | |||||
| Net Margin % | -235.05 | |||||
| FCF Margin % | -157.4 | |||||
| ROE % | -20.82 | |||||
| ROA % | -18.01 | |||||
| ROIC % | -22.9 | |||||
| 3-Year ROIIC % | 120.55 | |||||
| ROC (Joel Greenblatt) % | -207.41 | |||||
| ROCE % | -22.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.36 | |||||
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 3.53 | |||||
| EV-to-EBIT | -2.64 | |||||
| EV-to-Forward-EBIT | -2.62 | |||||
| EV-to-EBITDA | -3.86 | |||||
| EV-to-Forward-EBITDA | -3.02 | |||||
| EV-to-Revenue | 7.44 | |||||
| EV-to-Forward-Revenue | 8.62 | |||||
| EV-to-FCF | -5.27 | |||||
| Price-to-Net-Current-Asset-Value | 7.62 | |||||
| Price-to-Net-Cash | 10.58 | |||||
| Earnings Yield (Greenblatt) % | -37.88 | |||||
| FCF Yield % | -17.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OABI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OmniAb Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 26.391 | ||
| EPS (TTM) ($) | -0.6 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 50.09 | ||
| 14-Day RSI | 22.06 | ||
| 14-Day ATR ($) | 0.171902 | ||
| 20-Day SMA ($) | 2.55425 | ||
| 12-1 Month Momentum % | -35.97 | ||
| 52-Week Range ($) | 1.88 - 5.45 | ||
| Shares Outstanding (Mil) | 122.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OmniAb Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OmniAb Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
OmniAb Inc Frequently Asked Questions
What is OmniAb Inc(OABI)'s stock price today?
The current price of OABI is $1.91. The 52 week high of OABI is $5.45 and 52 week low is $1.88.
When is next earnings date of OmniAb Inc(OABI)?
The next earnings date of OmniAb Inc(OABI) is 2025-05-09 Est..
Does OmniAb Inc(OABI) pay dividends? If so, how much?
OmniAb Inc(OABI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers